Limited Offer
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Adenosine A2A Receptor Antagonists
- 1st Edition, Volume 170 - September 19, 2023
- Editors: Jiang-Fan Chen, Akihisa Mori
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 1 8 6 6 7 - 7
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 8 6 6 8 - 4
Adenosine A2A Receptor Antagonists, Volume 170 in the International Review of Neurobiology series highlights new advances in the field, with this new volume presenting in… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteAdenosine A2A Receptor Antagonists, Volume 170 in the International Review of Neurobiology series highlights new advances in the field, with this new volume presenting interesting chapters on a variety of timely topics, including A2A Adenosine Receptor Agonists, Antagonists, Inverse Agonists and Partial Agonist, Chemistry – agonists, antagonists, partial agonists, inverse agonists, Functional roles of adenosine receptors – biochemistry and neuronal plasticity, A2A and Depression, A2AR and glial function, The adenosine A2A receptor in the basal ganglia: expression in health and disease, heteromerization, functional selectivity and signaling, How and why A2a receptor become to be a therapeutic target in Parkinson’s disease therapy, and much more.
- Provides the authority and expertise of leading contributors from an international board of authors
- Presents the latest release in the International Review of Neurobiology
- Updated release includes the latest information on Adenosine A2A Receptor Antagonists
Undergraduates, graduates, academics, and researchers in the field of Adenosine A2A Receptor Antagonists
- Cover image
- Title page
- Table of Contents
- Series Page
- Copyright
- Contributors
- Preface
- Chapter One: A2A adenosine receptor agonists, antagonists, inverse agonists and partial agonists
- Abstract
- 1 Introduction
- 2 A2AAR agonists
- 3 Positive allosteric enhancers (PAMs)
- 4 A2AAR antagonists and inverse agonists
- 5 Negative allosteric enhancers (NAMs)
- 6 A2AAR partial agonists
- 7 Conclusions
- References
- Chapter Two: Adenosine A2A receptor and glia
- Abstract
- 1 Preface
- 2 A2AR in astrocytes
- 3 Astrocyte A2AR and Alzheimer’s disease
- 4 Astrocyte A2AR and PD
- 5 A2AR and microglia
- 6 Microglial A2A receptor and process retraction
- 7 Microglial A2A receptor and neuroinflammation
- 8 Microglial A2AR and AD
- 9 Microglial adenosine A2AR and PD
- 10 Microglial adenosine A2A receptor and stroke
- 11 Microglial A2AR in other diseases
- 12 Role of other microglial adenosine A1 and A3 receptors
- 13 A2AR and oligodendrocytes
- 14 Perspective
- References
- Chapter Three: The adenosine A2A receptor in the basal ganglia: Expression, heteromerization, functional selectivity and signalling
- Abstract
- Abbreviations
- 1 Introduction
- 2 Expression of A2AR in the basal ganglia
- 3 Functional selectivity and signalling of A2AR
- 4 Heteromer expression in neurological diseases affecting the basal ganglia and in alterations of the reward circuits by drugs of abuse
- 5 Concluding remarks
- Conflict of interests
- References
- Chapter Four: How and why the adenosine A2A receptor became a target for Parkinson’s disease therapy
- Abstract
- 1 Introduction
- 2 The relevance of the adenosinergic system and the A2A adenosine receptor
- 3 Adenosine A2A receptors and motor function
- 4 Adenosine A2A antagonists and dyskinesia
- 5 Adenosine A2A antagonists and motor function in Parkinson’s disease
- 6 Other potential mechanisms of action of A2A adenosine antagonists
- 7 Adenosine antagonists and non-motor symptoms of Parkinson’s disease
- 8 Exploring the future potential of adenosine A2A antagonists in Parkinson’s disease
- References
- Chapter Five: Adenosine A2A antagonists and Parkinson’s disease
- Abstract
- 1 Introduction
- 2 Receptor agonists
- 3 Inverse agonists
- 4 Receptor antagonists
- References
- Chapter Six: Effects of adenosine A2A receptors on cognitive function in health and disease
- Abstract
- 1 Introduction
- 2 Effects of A2A receptor modulation on normal cognitive function
- 3 Effects of A2A receptor modulation on cognitive impairments in aging and disease
- 4 Effects of A2A receptor modulation on cognitive impairments in stress
- 5 Effects of A2A receptor modulation on drug use and addiction
- 6 Conclusions
- References
- Chapter Seven: Adenosine A2A receptors and sleep
- Abstract
- 1 Introduction
- 2 Adenosine and its receptors
- 3 The role of adenosine and A2ARs in sleep-wake regulation
- 4 Conclusion
- References
- Chapter Eight: Adenosine A2A signals and dystonia
- Abstract
- Body
- References
- Chapter Nine: A2AR antagonist treatment for multiple sclerosis: Current progress and future prospects
- Abstract
- Abbreviation
- 1 Introduction
- 2 Adenosine metabolism
- 3 A2AR distribution in MS/EAE pathology
- 4 The confusing effect of A2AR signaling in MS/EAE
- 5 A2AR signaling in macrophages and dendritic cells
- 6 The complex effects of A2AR signaling in T cells
- 7 A2AR signaling is essential for maintaining the suppressive capacity of Tregs
- 8 A2AR antagonist attenuates the pro-inflammation phenotype of microglia
- 9 A2AR antagonist inhibits the activation of astrocytes
- 10 The A2AR antagonist protects oligodendrocytes from damage
- 11 A2AR antagonist protects against lymphocyte infiltration into the CNS across the BBB
- 12 A2AR antagonist suppresses T-cell infiltration by decreasing the ChP gateway activity
- 13 Safety of the A2AR antagonist in clinical trials
- 14 The limitations of current studies on the potential efficacy of A2AR antagonists in MS pathology
- 15 Conclusion
- References
- Chapter Ten: A2AR and traumatic brain injury
- Abstract
- 1 Preface
- 2 A2AR modulation of neuroinflammation at the early stage of TBI
- 3 A2AR modulation of glutamate excitotoxicity at the early stage of TBI
- 4 A2AR modulation of aberrant proteins
- 5 A2AR modulation of cognitive dysfunction after TBI
- 6 A2AR modulation of chronic neuroinflammation in TBI
- 7 A2AR modulation of other long-lasting consequences of TBI
- References
- Chapter Eleven: Chemobrain: An accelerated aging process linking adenosine A2A receptor signaling in cancer survivors
- Abstract
- 1 Introduction
- 2 Adenosine A2AR in cognitive function
- 3 Findings of cognitive dysfunction in chemobrain
- 4 Chemobrain as an accelerated aging phenotype in adult and pediatric cancer
- 5 The adenosine A2A receptor as a potential mechanism of accelerated aging in chemobrain and cancer
- 6 Concluding remarks
- References
- No. of pages: 324
- Language: English
- Edition: 1
- Volume: 170
- Published: September 19, 2023
- Imprint: Academic Press
- Hardback ISBN: 9780443186677
- eBook ISBN: 9780443186684
JC
Jiang-Fan Chen
Jiang-Fan Chen, MD, PhD, is an Associate Professor in the Boston University Medical Campus--Departments of Neurology and Pharmacology and Experimental Therapeutics. Dr. Chen’s research focuses on the neurobiology of adenosine and the A2A adenosine receptor and the role they may play in the development and treatment of neuropsychiatric disorders. Dr. Chen has developed an A2A receptor knockout mouse model and couples this genetic approach with pharmacological manipulation to explore the pathophysiological role of A2A receptors in animal and cellular models of neuropsychiatric disorders. The knowledge derived from these studies may provide the neurobiological basis for rational development of A2A receptor agents as treatment strategies for neuropsychological disorders, ranging from Parkinson’s disease to drug addiction.
Affiliations and expertise
Associate Professor, Departments of Neurology and Pharmacology and Experimental Therapeutics, Boston University Medical Center, MA, USAAM
Akihisa Mori
Akihisa Mori, Ph.D., is a global expert for Adenosine receptor neuroscience as well as Parkinson’s disease, having more than 3 decades experience to work for pharmaceutical industry from basic science, exploratory and translational research to global clinical development, for antiparkinsonian therapeutics. As for adenosine receptor neuroscience, he has discovered a functional significance of Adenosine A2A receptor in the basal ganglia as well as the adenosine A2A receptor antagonism mode of action as antiparkinsonian therapy. Also, he has made global leadership to develop a first-in class adenosine A2A receptor antagonist, Istradefylline, delivering the product to successful approval in the US and Japan. He has previously participated to be the Editor for volume 119 (Adenosine Receptors in Neurology and Psychiatry) of International Review of Neurobiology.
Affiliations and expertise
SNLD Ltd., Japan